News Kite outlines vision for next gen cancer killing cells Backed by Amgen, Kite outlines bold plan for developing CAR-T and TCR cells.
News Adaptimmune revives ovarian cancer trial T-cell trial will include controversial chemo agent fludarabine.
Views & Analysis Novartis committed to CAR-Ts - but doubts about commercial v... Novartis may have concerns about commercial prospects, says expert.